CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment
Cardiovascular diseases (CVDs) remain a significant global health challenge, with many current treatments addressing symptoms rather than the genetic roots of these conditions. The advent of CRISPR-Cas9 technology has revolutionized genome editing, offering a transformative approach to targeting dis...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/14/2/131 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588848539893760 |
|---|---|
| author | Klaudia Bonowicz Dominika Jerka Klaudia Piekarska Janet Olagbaju Laura Stapleton Munirat Shobowale Andrzej Bartosiński Magdalena Łapot Yidong Bai Maciej Gagat |
| author_facet | Klaudia Bonowicz Dominika Jerka Klaudia Piekarska Janet Olagbaju Laura Stapleton Munirat Shobowale Andrzej Bartosiński Magdalena Łapot Yidong Bai Maciej Gagat |
| author_sort | Klaudia Bonowicz |
| collection | DOAJ |
| description | Cardiovascular diseases (CVDs) remain a significant global health challenge, with many current treatments addressing symptoms rather than the genetic roots of these conditions. The advent of CRISPR-Cas9 technology has revolutionized genome editing, offering a transformative approach to targeting disease-causing mutations directly. This article examines the potential of CRISPR-Cas9 in the treatment of various CVDs, including atherosclerosis, arrhythmias, cardiomyopathies, hypertension, and Duchenne muscular dystrophy (DMD). The technology’s ability to correct single-gene mutations with high precision and efficiency positions it as a groundbreaking tool in cardiovascular therapy. Recent developments have extended the capabilities of CRISPR-Cas9 to include mitochondrial genome editing, a critical advancement for addressing mitochondrial dysfunctions often linked to cardiovascular disorders. Despite its promise, significant challenges remain, including off-target effects, ethical concerns, and limitations in delivery methods, which hinder its translation into clinical practice. This article also explores the ethical and regulatory considerations surrounding gene editing technologies, emphasizing the implications of somatic versus germline modifications. Future research efforts should aim to enhance the accuracy of CRISPR-Cas9, improve delivery systems for targeted tissues, and ensure the safety and efficacy of treatments in the long term. Overcoming these obstacles could enable CRISPR-Cas9 to not only treat but also potentially cure genetically driven cardiovascular diseases, heralding a new era in precision medicine for cardiovascular health. |
| format | Article |
| id | doaj-art-8f0e9db18bc84bfa8a4b3a8a5682c906 |
| institution | Kabale University |
| issn | 2073-4409 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj-art-8f0e9db18bc84bfa8a4b3a8a5682c9062025-01-24T13:26:48ZengMDPI AGCells2073-44092025-01-0114213110.3390/cells14020131CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for TreatmentKlaudia Bonowicz0Dominika Jerka1Klaudia Piekarska2Janet Olagbaju3Laura Stapleton4Munirat Shobowale5Andrzej Bartosiński6Magdalena Łapot7Yidong Bai8Maciej Gagat9Department of Histology and Embryology and Vascular Biology Student Research Club, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-092 Bydgoszcz, PolandDepartment of Histology and Embryology and Vascular Biology Student Research Club, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-092 Bydgoszcz, PolandDepartment of Histology and Embryology and Vascular Biology Student Research Club, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-092 Bydgoszcz, PolandDepartment of Histology and Embryology and Vascular Biology Student Research Club, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-092 Bydgoszcz, PolandDepartment of Histology and Embryology and Vascular Biology Student Research Club, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-092 Bydgoszcz, PolandDepartment of Histology and Embryology and Vascular Biology Student Research Club, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-092 Bydgoszcz, PolandFaculty of Medicine, Collegium Medicum, Mazovian Academy in Płock, 09-402 Płock, PolandFaculty of Medicine, Collegium Medicum, Mazovian Academy in Płock, 09-402 Płock, PolandDepartment of Cell Systems and Anatomy, UT Health, Long School of Medicine, San Antonio, TX 78229, USADepartment of Histology and Embryology and Vascular Biology Student Research Club, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-092 Bydgoszcz, PolandCardiovascular diseases (CVDs) remain a significant global health challenge, with many current treatments addressing symptoms rather than the genetic roots of these conditions. The advent of CRISPR-Cas9 technology has revolutionized genome editing, offering a transformative approach to targeting disease-causing mutations directly. This article examines the potential of CRISPR-Cas9 in the treatment of various CVDs, including atherosclerosis, arrhythmias, cardiomyopathies, hypertension, and Duchenne muscular dystrophy (DMD). The technology’s ability to correct single-gene mutations with high precision and efficiency positions it as a groundbreaking tool in cardiovascular therapy. Recent developments have extended the capabilities of CRISPR-Cas9 to include mitochondrial genome editing, a critical advancement for addressing mitochondrial dysfunctions often linked to cardiovascular disorders. Despite its promise, significant challenges remain, including off-target effects, ethical concerns, and limitations in delivery methods, which hinder its translation into clinical practice. This article also explores the ethical and regulatory considerations surrounding gene editing technologies, emphasizing the implications of somatic versus germline modifications. Future research efforts should aim to enhance the accuracy of CRISPR-Cas9, improve delivery systems for targeted tissues, and ensure the safety and efficacy of treatments in the long term. Overcoming these obstacles could enable CRISPR-Cas9 to not only treat but also potentially cure genetically driven cardiovascular diseases, heralding a new era in precision medicine for cardiovascular health.https://www.mdpi.com/2073-4409/14/2/131cardiovascular diseases (CVDs)CRISPR-Cas9gene therapymitochondrial genome editing |
| spellingShingle | Klaudia Bonowicz Dominika Jerka Klaudia Piekarska Janet Olagbaju Laura Stapleton Munirat Shobowale Andrzej Bartosiński Magdalena Łapot Yidong Bai Maciej Gagat CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment Cells cardiovascular diseases (CVDs) CRISPR-Cas9 gene therapy mitochondrial genome editing |
| title | CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment |
| title_full | CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment |
| title_fullStr | CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment |
| title_full_unstemmed | CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment |
| title_short | CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment |
| title_sort | crispr cas9 in cardiovascular medicine unlocking new potential for treatment |
| topic | cardiovascular diseases (CVDs) CRISPR-Cas9 gene therapy mitochondrial genome editing |
| url | https://www.mdpi.com/2073-4409/14/2/131 |
| work_keys_str_mv | AT klaudiabonowicz crisprcas9incardiovascularmedicineunlockingnewpotentialfortreatment AT dominikajerka crisprcas9incardiovascularmedicineunlockingnewpotentialfortreatment AT klaudiapiekarska crisprcas9incardiovascularmedicineunlockingnewpotentialfortreatment AT janetolagbaju crisprcas9incardiovascularmedicineunlockingnewpotentialfortreatment AT laurastapleton crisprcas9incardiovascularmedicineunlockingnewpotentialfortreatment AT muniratshobowale crisprcas9incardiovascularmedicineunlockingnewpotentialfortreatment AT andrzejbartosinski crisprcas9incardiovascularmedicineunlockingnewpotentialfortreatment AT magdalenałapot crisprcas9incardiovascularmedicineunlockingnewpotentialfortreatment AT yidongbai crisprcas9incardiovascularmedicineunlockingnewpotentialfortreatment AT maciejgagat crisprcas9incardiovascularmedicineunlockingnewpotentialfortreatment |